Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

Abstract The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fabio Puglisi, Lorenzo Gerratana, Matteo Lambertini, Marcello Ceppi, Luca Boni, Filippo Montemurro, Stefania Russo, Claudia Bighin, Michelino De Laurentiis, Mario Giuliano, Giancarlo Bisagni, Antonio Durando, Anna Turletti, Ornella Garrone, Andrea Ardizzoni, Teresa Gamucci, Giuseppe Colantuoni, Adriano Gravina, Sabino De Placido, Francesco Cognetti, Lucia Del Mastro
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/76849692dd90493e9b9efa13c03d952c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:76849692dd90493e9b9efa13c03d952c
record_format	dspace
spelling	oai:doaj.org-article:76849692dd90493e9b9efa13c03d952c2021-12-02T18:19:00ZComposite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer10.1038/s41523-021-00286-w2374-4677https://doaj.org/article/76849692dd90493e9b9efa13c03d952c2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00286-whttps://doaj.org/toc/2374-4677Abstract The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an ancillary analysis of the GIM2 trial evaluating the absolute treatment effect through a composite measure of recurrence risk (CPRS) in patients with hormone receptor-positive HER2-negative eBC. CPRS was estimated through Cox proportional hazards models applied to the different clinicopathological features. The treatment effect was compared to the values of CPRS by using the Sub-population Treatment Effect Pattern Plot (STEPP) process. The Disease-Free Survival (DFS)-oriented STEPP analysis showed distinct patterns of relative treatment effect with respect to CPRS. Overall, 5-year DFS differed across CPRS quartiles ranging from 95.2 to 66.4%. Each CPRS quartile was characterized by a different patients’ composition, especially for age, lymph node involvement, tumor size, estrogen and progesterone receptor expression, and Ki-67. A number needed to treat of 154 and 6 was associated with the lowest and the highest CPRS quartile, respectively. Dose-dense adjuvant chemotherapy showed a consistent benefit in node-positive eBC patients with hormone receptor-positive HER2-negative disease, but its effect varied according to CPRS.Fabio PuglisiLorenzo GerratanaMatteo LambertiniMarcello CeppiLuca BoniFilippo MontemurroStefania RussoClaudia BighinMichelino De LaurentiisMario GiulianoGiancarlo BisagniAntonio DurandoAnna TurlettiOrnella GarroneAndrea ArdizzoniTeresa GamucciGiuseppe ColantuoniAdriano GravinaSabino De PlacidoFrancesco CognettiLucia Del MastroNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Fabio Puglisi Lorenzo Gerratana Matteo Lambertini Marcello Ceppi Luca Boni Filippo Montemurro Stefania Russo Claudia Bighin Michelino De Laurentiis Mario Giuliano Giancarlo Bisagni Antonio Durando Anna Turletti Ornella Garrone Andrea Ardizzoni Teresa Gamucci Giuseppe Colantuoni Adriano Gravina Sabino De Placido Francesco Cognetti Lucia Del Mastro Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
description	Abstract The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an ancillary analysis of the GIM2 trial evaluating the absolute treatment effect through a composite measure of recurrence risk (CPRS) in patients with hormone receptor-positive HER2-negative eBC. CPRS was estimated through Cox proportional hazards models applied to the different clinicopathological features. The treatment effect was compared to the values of CPRS by using the Sub-population Treatment Effect Pattern Plot (STEPP) process. The Disease-Free Survival (DFS)-oriented STEPP analysis showed distinct patterns of relative treatment effect with respect to CPRS. Overall, 5-year DFS differed across CPRS quartiles ranging from 95.2 to 66.4%. Each CPRS quartile was characterized by a different patients’ composition, especially for age, lymph node involvement, tumor size, estrogen and progesterone receptor expression, and Ki-67. A number needed to treat of 154 and 6 was associated with the lowest and the highest CPRS quartile, respectively. Dose-dense adjuvant chemotherapy showed a consistent benefit in node-positive eBC patients with hormone receptor-positive HER2-negative disease, but its effect varied according to CPRS.
format	article
author	Fabio Puglisi Lorenzo Gerratana Matteo Lambertini Marcello Ceppi Luca Boni Filippo Montemurro Stefania Russo Claudia Bighin Michelino De Laurentiis Mario Giuliano Giancarlo Bisagni Antonio Durando Anna Turletti Ornella Garrone Andrea Ardizzoni Teresa Gamucci Giuseppe Colantuoni Adriano Gravina Sabino De Placido Francesco Cognetti Lucia Del Mastro
author_facet	Fabio Puglisi Lorenzo Gerratana Matteo Lambertini Marcello Ceppi Luca Boni Filippo Montemurro Stefania Russo Claudia Bighin Michelino De Laurentiis Mario Giuliano Giancarlo Bisagni Antonio Durando Anna Turletti Ornella Garrone Andrea Ardizzoni Teresa Gamucci Giuseppe Colantuoni Adriano Gravina Sabino De Placido Francesco Cognetti Lucia Del Mastro
author_sort	Fabio Puglisi
title	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
title_short	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
title_full	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
title_fullStr	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
title_full_unstemmed	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
title_sort	composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/76849692dd90493e9b9efa13c03d952c
work_keys_str_mv	AT fabiopuglisi compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT lorenzogerratana compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT matteolambertini compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT marcelloceppi compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT lucaboni compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT filippomontemurro compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT stefaniarusso compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT claudiabighin compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT michelinodelaurentiis compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT mariogiuliano compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT giancarlobisagni compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT antoniodurando compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT annaturletti compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT ornellagarrone compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT andreaardizzoni compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT teresagamucci compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT giuseppecolantuoni compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT adrianogravina compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT sabinodeplacido compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT francescocognetti compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer AT luciadelmastro compositeriskandbenefitfromadjuvantdosedensechemotherapyinhormonereceptorpositivebreastcancer
_version_	1718378162271813632

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

Ejemplares similares